bufomix easyhaler 9+320 mikrog/dosis inhalationspulver
paranova danmark a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 9+320 mikrog/dosis
berodual 50 + 20 mikrog./pust inhalationsspray, opløsning
boehringer ingelheim int. gmbh - fenoterolhydrobromid, ipratropiumbromid - inhalationsspray, opløsning - 50 + 20 mikrog./pust
incruse ellipta (previously incruse)
glaxosmithkline (ireland) limited - umeclidiniumbromid - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - indikeret som vedligeholdelsesbronkodilatorbehandling for at lindre symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (copd).
rolufta ellipta (previously rolufta)
glaxosmithkline trading services limited - umeclidiniumbromid - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - rolufta er indiceret som vedligeholdelsesbronkodilatorbehandling for at lindre symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (copd).
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
symbicort forte turbohaler 9+320 mikrog./dosis inhalationspulver
2care4 aps - budesonid, formoterolfumarat dihydrat - inhalationspulver - 9+320 mikrog./dosis
symbicort forte turbohaler 9+320 mikrog/dosis inhalationspulver
paranova danmark a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 9+320 mikrog/dosis
symbicort forte turbuhaler 9+320 mikrog./dosis inhalationspulver
europharma.dk aps - budesonid, formoterolfumarat dihydrat - inhalationspulver - 9+320 mikrog./dosis
exubera
pfizer limited - insulin human - diabetes mellitus - narkotika anvendt i diabetes - exubera er indiceret til behandling af voksne patienter med type 2-diabetes mellitus notadequately kontrolleret med oral antidiabetika, og der kræver insulin terapi. exubera er også indiceret til behandling af voksne patienter med type 1 diabetes mellitus, inaddition for lang tid eller mellemliggende handler subkutan insulin, for hvem de potentielle fordele ofadding inhaleret insulin opvejer de potentielle sikkerhedsproblemer (se afsnit 4.